Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV: ₹ 17.1 as on 24-03-2023
Fund Performance
302 people have invested ₹ 7.2L in mutual fund in the last three months
Fund Insights
In the last 1 year, SBI Healthcare Opportunities Fund Direct Growth has given -2.81% return, outperforming Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth by 8.23%
In the last 3 years, DSP Healthcare Fund Direct Growth has given 29.51% return, outperforming Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth by 8.08% per annum
Over the last 1 month, Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has increased expense ratio by 12.5% moving from 1.04 to 1.17
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.17% which is lower than the category average expense ratio of 1.67%
INDmoney Rank
Powered by IND quant engine
IND ranking is not available for this fund.
Pros
Hold on while we find any good points for this fund.
Cons
3Y returns in the bottom 25% of the category
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Performance as on (24-Mar-23)
About the Fund
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is an equity fund. This fund was started on 11 July, 2019. The fund is managed by Dhaval Shah. The fund could potentially beat inflation in the long-run.
Key parameters
1) Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has a NAV of ₹17.08 as on 24-03-2023.
2) Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has ₹425 Cr worth of assets under management (AUM) as on 31-01-2023 and is less than category average.
3) The fund has an expense ratio 1.17 %.
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Overview
 | 1.17% |
 Benchmark | S&P BSE Healthcare PR |
 | ₹425 Cr |
 | 11 July, 2019 |
 | ₹1000/₹500 |
 Exit Load | 1% |
 | No Lock-in |
 TurnOver | 64.89% |
Fund Distribution as on (28-Feb-23)
Size breakup
Large cap
43.9%
Mid cap
25.3%
Small cap
25.1%
Sector Allocation
Health
97.6%
Basic Materials
1.3%
Consumer Defensive
1%
Top Holdings of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth as on (28-Feb-23)
Equity Holdings31
Holdings | Weight% | Holdings Trend | 1M Change |
|---|---|---|---|
 Sun Pharmaceuticals Industries Ltd | 17.23% | 0% | |
 Apollo Hospitals Enterprise Ltd | 9.72% | 0% | |
 Dr Reddy's Laboratories Ltd | 7.57% | 0% | |
 Lupin Ltd | 5.19% | 0% | |
 Fortis Healthcare Ltd | 5.07% | 0% |
See all
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth: Monthly Changes Updates
All changes are between Dec'22 and Feb'23
Fund Performance
- This fund’s returns stands at -2.54% whereas the fund’s underlying benchmark Nifty 500 returns stands at -2.22% as on Feb'23
- This fund underperformed Nifty 500 by 0.33% in Feb'23
AUM Change
- AUM of the fund stands at 425.5 Cr as of Feb'23
- AUM decreased by 14.3 Cr between Feb'23 and Jan'23
Fund Portfolio Changes
Top Stocks bought last month
Sun Pharmaceuticals Industries Ltd's allocation increased from 16.97% to 18.03%
Dr Reddy's Laboratories Ltd's allocation increased from 6.85% to 7.34%
J.B. Chemicals & Pharmaceuticals Ltd's allocation increased from 2.88% to 3.17%
Top Stocks sold last month
Cipla Ltd's allocation decreased from 9.64 % to 9.39 %
Apollo Hospitals Enterprise Ltd's allocation decreased from 9.11 % to 9.09 %
Indoco Remedies Ltd's allocation decreased from 3.25 % to 2.75 %
Small Cap allocation has gone up from 24.8% to 25.1%
Mid Cap allocation has gone up from 23.2% to 25.3%
Large Cap allocation has gone down from 50.4% to 43.9%
Cash allocation has gone up from 1.6% to 5.7%
Top 3 Sectors in February were Health, Basic Materials & Consumer Defensive
Feb'23
Health
98%
Basic Materials
1%
Consumer Defensive
1%
Jan'23
Health
98%
Basic Materials
1%
Consumer Defensive
Gainers & Losers in Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth portfolio as on (28-Feb-23)
Top Growth Drivers | 1M Return |
|---|---|
Global Health Ltd | 21% |
 Indoco Remedies Ltd | 10.5% |
 Apollo Hospitals Enterprise Ltd | 3.3% |
Peer Analysis
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Fund Manager
Dhaval Shah
Fund Manager of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth, since 11 July 2019
Top funds managed
Fund Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 15.4% since inception which is more than its category average return of 13.52%
Fund Allocations
This fund has an allocation of 94.34% in Equity, 0% in Debt and 5.66% in Cash related instruments
AUM size ₹425 Cr
This fund has AUM of ₹425 Cr which is less than its category average of ₹ 1251 Cr
Expense Ratio 1.17%
This fund has an expense ratio of 1.17% which is less than its category average expense ratio of 1.56%
Frequently Asked Questions
The current NAV of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is 17.16 as on 23-Mar-2023.
Existing (Absolute + CAGR)
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | -1.72% | -1.72% |
6 Month Returns | -3.87% | -3.87% |
1 Year Returns | -9.54% | -9.54% |
3 Years Returns | 82.36% | 22.17% |
5 Years Returns | 0% | 0% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
1.17 as on February 2023
425 Cr as on February 2023
Sun Pharmaceuticals Industries Ltd(17.23%),Apollo Hospitals Enterprise Ltd(9.72%),Dr Reddy's Laboratories Ltd(7.57%),Lupin Ltd(5.19%),Fortis Healthcare Ltd(5.07%) as on February 2023
Health(92.11%),Cash Equivalent(5.66%),Basic Materials(1.25%) as on February 2023
The alpha ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | 0.48 | -0.89 | - |
As on February 2023
The alpha for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | 0.91 | 0.9 | - |
As on February 2023
The Beta for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | -0.79 | 0.59 | - |
As on February 2023
The sharpe ratio for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth | 12.62 | 20.53 | - |
As on February 2023
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.15 as on February 2023. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Dhaval Shah is the fund manager of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
The Exit load of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is 1%